RBC Capital Reiterates Outperform on Definium Therapeutics, Maintains $66 Price Target

Benzinga · 3d ago
RBC Capital analyst Brian Abrahams reiterates Definium Therapeutics (NASDAQ:DFTX) with a Outperform and maintains $66 price target.